Cynbiose, Signia Therapeutics and the VirPath academic laboratory are partnering on an ambitious collaborative R&D project to advance the development of innovative therapeutic treatments in the field of respiratory infections.

The METABIOSE project aims to develop and characterize a translational model of metapneumovirus
infection (hMPV), then to validate in preclinical studies a drug repositioned as a pneumovirus inhibitor
from Signia Therapeutics’s portfolio, as well as a new nebulization delivery thanks to an approved
medical device.

Read the press release.